News & Events

October 12th, 2022

IPA’s subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs

  Under strategic collaboration, Talem, an IPA subsidiary, expands its relationship with Ligand/OmniAb, Inc., to develop three immuno-oncology programs targeting validated targets Talem intends to leverage IPA’s broad range…

September 14th, 2022

NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75

VICTORIA, BRITISH COLUMBIA (CANADA), September 14, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), announced today that its subsidiary, Talem Therapeutics LLC (“Talem”), has…

September 14th, 2022

IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023

  Structural HYFTs fully indexed and integrated in structure-function workflow LENSai® data management platform successfully launches hyper-scalable solution for partner access, integrating multiple data layers at once Company shares…